Moderna CEO says vaccines likely less effective against Omicron

News

02.12.2025 | 18:15
Euromoney Names Ameriabank Armenia’s Best Bank for Real Estate for the Second Year in a Row
02.12.2025 | 10:00
S&P Global Ratings has assigned IDBank CJSC a long-term rating of “BB-” and a short-term rating of “B” with a “stable” prospect.
26.11.2025 | 10:00
Thanks to 129 million drams of donation from Karen Vardanyan, 17 new musical instruments were provided to the Armenian National Philharmonic Orchestra.
13.11.2025 | 19:10
War of Words: Why the Kremlin and Baku Speak the Same Language
23.10.2025 | 22:00
When the border passes through the house: Baarle, one village with two states
23.10.2025 | 14:29
Dubai Chamber of Commerce organises bilateral business forum in Yerevan to strengthen trade and investment cooperation with Armenia
16.10.2025 | 15:48
200 Scholarships for the Best Students. Ameriabank Announces a Contest for the Second Year in a Row
18.09.2025 | 15:45
Women in Agriculture: Europe’s Slowly Changing Reality
17.09.2025 | 11:57
Thanks to Barerar.am, more than 50 families’ lives were transformed in just one year
11.09.2025 | 16:30
Beyond Geopolitics: The Human Face of the EU Mission
30.05.2025 | 10:55
Mikael Vardanyan provided 3 neonatal emergency vehicles and the medical equipment amounting 118 million AMD to the Muratsan hospital complex
22.05.2025 | 11:09
Musical fountains in the Yerevan 2800th Anniversary Park
18.03.2025 | 12:45
Azerbaijan has not provided with any factual evidence of a ceasefire violation by the Armenian army: The statement of the Prime Minister’s Office
11.03.2025 | 12:23
Barerar.am  platform – the unique opportunity to become a true philanthropist
26.02.2025 | 20:08
Garant Logistics completes first cargo transportation on new China-Armenia land route
More

The head of drugmaker Moderna  said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic, Reuters reported.

“There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,” Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview. “I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . . are like ‘this is not going to be good.'”

Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.